Replay Therapeutics

Replay is a genome writing company that utilizes a unique hub-and-spoke model to develop next-generation genetic medicines. The company's core technology stack includes synHSV, a high-capacity genomic herpes simplex virus vector capable of delivering genetic payloads up to 150kb, and uCell, a universal iPSC-derived cell therapy platform. Replay operates through several specialized spoke companies, such as Syena for oncology and Eudora for retinal diseases, each focused on specific therapeutic areas. By integrating advanced DNA synthesis and computational design, Replay aims to overcome the payload limitations of traditional viral vectors and create more effective therapies for complex and polygenic diseases. The company is backed by prominent investors and maintains a significant presence in both San Diego and London.